title icon
Less relapse. More recovery

We engineer immune cells to be warriors

Overcoming relapse rates in blood born cancers. At Luminary, we are keenly focused on meeting this and many other challenges. We are developing cellular therapies that bring new advances to the table. Our work is helping to deliver new standards of care for specific B-Cell mediated autoimmune diseases. At the same time, we are delivering ground-breaking science for solid tumors. And we are doing this at lower therapy costs.

Less relapse, more recovery, less financial strain. This is our mission.

test tube image
title icon

Three times more likely to bind to the target cancer cells

In the vast universe of CAR-T immunotherapies, there are still challenges to overcome. Our R&D team has recently put forth some eye-opening results. Leading the way is our novel single CAR. Using three receptors, it is designed to overcome a major deficiency of the single antigen CAR–antigen escape. This single antigen approach results in failure rates between 25% and 30%, depending on the type of cancer.

Our 3-receptor CAR first identifies multiple targets on cancer cells. It then surrounds and attaches to these cells in three ways instead of one, allowing fewer escape routes and increasing overall cancer-killing effectiveness.

baff cart-t cell diagram
title icon

Less recurrence. More recovery.

By aggressively pursuing BAFF CAR-T therapy, we add three times the targeting to the equation.
As a result, we expect to lower relapse rates dramatically.

30-60% of cancer patients relapse after CD19 CAR-T cell treatment. Cancer cells evade the immune system by mutating CD19 off the cell surface and the persistence of CAR T-cells.

title icon
Split Co-Stim Dual CAR

Breakthrough Solid Tumor Programs

Luminary Therapeutics is combining CAR T design elements in novel ways to overcome the unique challenges presented by the solid tumor microenvironment. Our solid tumor program utilizes a Dual CAR architecture to target multiple cancer antigens and more completely eradicate cancerous cells with a single engineered T cell product. We have optimized our costimulatory domain arrangement to prevent T cell exhaustion and enhance persistence. Finally, the large genetic cargo capacity of the Tc Buster transposon system allows us to include cytokine sinks to neutralize immunosuppressive signals in the tumor microenvironment.

title icon
Gamma 2.0+ Allogeneic Platform

Allogeneic is the holy grail. We have broken the code.

Patients need “off the shelf” therapies to reduce time for treatment and cure. Allogeneic solutions are being highly sought. Luminary Therapeutic’s promising Gamma Delta solution is currently in nonclinical evaluation. Expansion rates are high; in vivo pilot studies are underway. Results are very promising.

Unlike other single subset approaches, our Gamma Delta two subset (Vδ1 and Vδ2) solution creates double the response to cancer killing that is both innate and adaptive.

non-viral allogeneic platform

More “adaptive-like”

  • Cytotoxicity against hematological malignancies
  • Less susceptible to activation-induced cell death/exhaustion
  • Multi-year persistence documented in patients
non-viral allogeneic platform

More “innate-like”

  • Abundant in peripheral blood
  • Cytotoxicity against hematological malignancies
  • Readily expanded in vitro (zoledronate)
title icon

Improved quality and reduced risk in the same system

Compared to virus-based systems, non-viral gene editing systems have dramatically changed the manufacturing landscape and improved safety. With higher integration rates and faster manufacturing cycles, these systems are rapidly gaining acceptance in the industry. Luminary Therapeutics utilizes a non-viral gene editing system, TcBuster, to manufacture CAR-T cells. TcBuster was developed by B-MoGen, a company formed by the founders of Luminary , and sold to Bio-Techne prior to the creation of Luminary.

Benefits of TcBuster’s non-viral gene modification:

  • Allows for stable integration of large cargo (>10kb)
  • Preferred integration profile compared to retro/lentiviral vectors
  • Generated GMP grade tranposon reagents in <4 months
  • Lower engineering cost than viral vectors by 75-90%
transposase mRNA